Researchers at The University of Texas MD Anderson Cancer Center built a new atlas of lung cells, uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the ...

When the patient opted against surveillance CT scans and a follow-up PET scan, her physician ordered the CyPath® Lung test in March 2025. The test result of 0.56 – classified as “likely malignancy” – ...

Lung Adenocarcinoma Rates on the Rise, Mostly in Nonsmokers A study published last month in The Lancet reported that adenocarcinoma makes up as much as 70% of lung cancer cases among people who ...

BERGEN, Norway, Jan. 7, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer ...

About TUB-040 and the P5 Technology Tubulis’ lead antibody-drug conjugate (ADC) TUB-040 is directed against Napi2b, an antigen highly overexpressed in ovarian cancer and lung adenocarcinoma.